Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05273151
Other study ID # PM009
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 4, 2023
Est. completion date June 15, 2025

Study information

Verified date April 2024
Source Chordate Medical
Contact Peter J Goadsby, Prof,MD, PhD
Phone +44-20-3299 3106
Email peter.goadsby@kcl.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An open pilot study, non-controlled, single center investigation.


Description:

An open pilot study, non-controlled, single center investigation. The study consists of a 4-week screening period, a 6-week treatment period, and a 12 week follow-up period. Subjects who provided written informed consent and are eligible for the study will be asked to complete a daily diary for 4 weeks during the screening period. In the diary the subjects will record headache and migraine days, any changes in their health, and concomitant medications they may be using. The data collected in the diary during this screening period will be used as Baseline for the performance assessments. Subjects who completed the screening period and continue to meet the eligibility criteria after review of diary entries by the investigator will receive treatment. The subjects will receive 6 treatments with the Chordate System S220 at weekly intervals at the site (Day 0 to 35; treatment Visit [V] 1 to 6) and continue to maintain a daily diary. After completion of the 6-week study treatment period (V1 to V6), subjects will be treated monthly and followed up for another 12 weeks. The final visit will be performed on Day 125, 12 weeks after the last study treatment. During the 12-week follow-up, the subjects will continue to complete a daily diary.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date June 15, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria 1. The subject is legally competent, has been informed of the nature, the scope and the relevance of the study, voluntarily agrees to participation and the study's provisions, and has duly signed the informed consent form. 2. Male or female aged between 18 and 70 years (inclusive) at the time of providing informed consent. 3. Diagnosed as suffering from chronic migraine with or without aura (=15 headache days per month including at least 8 migraine days for more than 3 months before screening) according to the International Headache Society classification (International Classification of Headache Disorders III); 4. Migraine onset before the age of 50 years. 5. Reported history of migraine for at least 1 year before screening. 6. If subjects are on a preventive treatment at the time of screening, this must have been stable over the preceding 3 months. 7. If subjects are on preventive treatment at the time of screening, they have to be able and willing to maintain current preventive treatment regimen (no change in type, frequency or dose) from screening to end of follow- 8. Failed at least 3 different preventive medications and 3 months of treatment with a monoclonal antibody targeting the CGRP pathway. 9. Women of childbearing potential must be willing to use highly effective contraceptive methods (failure rate <1% per year when used consistently and correctly) during the study. Exclusion Criteria 1. Unable to distinguish between migraine and other headache types. 2. An ongoing upper respiratory infection, nasal tumors, or wounds in the nasal cavity. 3. Nasal cavity abnormalities that prevents catheter insertion. 4. A concomitant condition that could cause excessive nose bleeding or ongoing treatment with anticoagulant medication (except Aspirin and Clopidogrel). 5. A known allergy to polyurethane (polyurethane is used in the catheter balloon). 6. Systemic diseases with manifestations in the nose. 7. Previous treatment with radiation therapy to the nasal area. 8. Nasal surgery performed within the last six months. 9. Concurrent condition or risk of non-compliance that, in the investigator's opinion, may affect the interpretation of performance or safety data or which otherwise contraindicates participation in a clinical investigation; 10. Pregnant and lactating women; 11. Participation in a clinical investigation within 3 months of enrolment or planned participation at any time during this clinical investigation; 12. Previous participation in this study; 13. Employees of the study site or the sponsor directly involved with the conduct of the study, or immediate family members of any such individuals;

Study Design


Related Conditions & MeSH terms


Intervention

Device:
KOS (Intranasal kinetic oscillation stimulation)
Treatment is 10 minutes in each nasal cavity. Totally 2 x 10 minutes per treatment.

Locations

Country Name City State
United Kingdom Wolfson Centre for Age-Related Diseases Institute of Psychiatry, Psychology and Neuroscience Wellcome Foundation Building, Denmark Hill Campus King's College London

Sponsors (1)

Lead Sponsor Collaborator
Chordate Medical

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean change in headache days Change in headache days with moderate to severe intensity after 6 weeks of treatment. Headache days are collected in eDiary baseline to 6 weeks
Secondary Mean change in Migraine days Mean change of migraine days, responder rate, use of abortive medication, health-related quality of life and disability, and patient's global impression of severity 12 weeks (90 days) Migraine days is collected in an eDiary. Baseline to 12 weeks
Secondary Incidence of adverse events (AEs) and adverse device effects (ADEs) All adverse events (AEs) and adverse device effects (ADEs) incidence and severity following treatment with the Chordate System 220 Baseline to 12 weeks
Secondary Number of patients who are responders Responders are classified as responder (less migraine/headache days) or non-responder (same or worsening of migraine/headache days).
A respondes is a patient who has decrease of headaches/migraine days whilst a non responder had no or the same number of headache/migraine days
baseline to 12 weeks
Secondary Number of patients who decrease use of abortive medication Intake of abortive medications are registred in eDiary and will be calculated on patient level baseline to 12 weeks
Secondary Mean change in Hospital Anxiety and Depression Scale (HADS) HADS is a scale with 7 questions related to anxiety and 7 questions related to depression Anxiety can have 0-21 points (lower score means no anxiety) and Depression 0-21 points (higher score means no depression) baseline to 12 weeks
Secondary Mean change in Headache Impact Test (HIT-6) HIT-6 consist of 6 questions HIT-6 with scores from 6 to 13 where 13 is worst case per question so lower score means less problems baseline to 12 weeks
Secondary Mean change in Subject global severity Patient Global severity is a scale with four (4) scores, where normal (0) is the lowest and show no problems whilst severe (3) is the worst score 0=Normal
Mild
Moderate
Severe
baseline to 12 weeks
Secondary Mean change in headache days Change in headache days with moderate to severe intensity from eDiary week 6-12
See also
  Status Clinical Trial Phase
Completed NCT05720819 - Biofeedback-VR for Treatment of Chronic Migraine N/A
Not yet recruiting NCT06428838 - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context Phase 3
Recruiting NCT05517200 - Pilot Study for a Machine Learning Test for Migraine
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Completed NCT02514148 - Biobehavioral Physical Therapy Strategies Based on Therapeutic Exercise Applied to Chronic Migraine Patients N/A
Enrolling by invitation NCT02291380 - A Study to Evaluate Botulinum Toxin Type A for Injection(HengLi®)for Prophylactic Treatment of Chronic Migraine Phase 3
Withdrawn NCT02122744 - RCT Versus Placebo of rTMSQP Over Visual Cortex for the Prevention of Chronic Migraine N/A
Completed NCT02122237 - Cathodal tDCS in Chronic Migraine: Neurophysiological Study and Pilot Therapeutic Trial Phase 3
Recruiting NCT02202486 - Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI N/A
Completed NCT01709708 - Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine Phase 4
Completed NCT01741246 - Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomography and Magnetic Resonance Imaging N/A
Completed NCT01090050 - Treximet in the Treatment of Chronic Migraine Phase 4
Recruiting NCT03507400 - Introvision for Migraine and Headaches N/A
Completed NCT04161807 - Efficacy and Safety of Nerivio™ for Acute Treatment of Migraine in People With Chronic Migraine N/A
Completed NCT03175263 - OnabotulinumtoxinA Injections in Chronic Migraine, Targeted to Sites of Pericranial Myofascial Pain N/A
Withdrawn NCT04353505 - Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache Phase 1
Completed NCT01667250 - Non-Invasive Neurostimulation for the Prevention of Chronic Migraine N/A
Completed NCT01700387 - A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency Phase 4
Not yet recruiting NCT01135784 - Study of MIGRA-ZEN RELIEF PLUS In the Treatment of Chronic Migraine Headache Phase 2
Completed NCT01496950 - Double-blind Randomized Clinical Trial of Transcranial Magnetic Stimulation in Chronic Migraine Phase 1